Glycaemic outcomes in adults with type 1 diabetes transitioning towards advanced automated insulin delivery systems - a real-world analysis at a Swiss tertiary centre

被引:1
|
作者
Lehmann, Vera [1 ]
Noti, Franco [1 ]
Laimer, Markus [1 ]
Stettler, Christoph [1 ]
Zuger, Thomas [1 ,2 ]
机构
[1] Univ Bern, Bern Univ Hosp, Inselspital, Dept Diabet Endocrinol Nutr Med & Metab, CH-3010 Bern, Switzerland
[2] Kantonsspital Olten, Dept Diabet Endocrinol & Metab Dis, Olten, Switzerland
关键词
HYBRID CLOSED-LOOP;
D O I
10.57187/s.3501
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AIMS OF THE STUDY: To assess glucose levels in adults with diabetes at a Swiss tertiary hospital when transitioning from insulin delivery with a sensor-augmented pump with (predictive) low-glucose suspend ([P]LGS) to a hybrid-closed loop (HCL) and from a HCL to an advanced hybrid-closed loop (AHCL). METHODS: Continuous glucose monitoring data for 44 adults with type 1 diabetes transitioning from (P)LGS to hybrid-closed loop and from hybrid-closed loop to advanced hybrid-closed loop were analysed, including the percentage of time spent within, below, and above glucose ranges. In addition, a subgroup analysis (n = 14) of individuals undergoing both transitions was performed. RESULTS: The transition from a (P)LGS to a hybrid-closed loop was associated with increased time in range (6.6% [2.6%-12.7%], p <0.001) and decreased time above range (5.6% [2.3%-12.7%], p <0.001). The transition from a hybrid-closed loop to an advanced hybrid-closed loop was associated with increased time in range (1.6% [-0.5%-4.5%], p = 0.046) and decreased time above range (1.5% [-1.8%-5.6%], p = 0.050). Both transitions did not change the time below range. In the subgroup analysis ([P]LGS. HCL. AHCL), the time in range increased from 69.4% (50.3%-79.2%) to 76.5% (65.3%-81.3%) and 78.7% (69.7%-85.8%), respectively (p <0.001). CONCLUSIONS: Glucose levels significantly improved when transitioning from a (P)LGS to a hybrid-closed loop. Glucose levels improved further when switching from a hybrid-closed loop to an advanced hybrid-closed loop. However, the added benefit of an advanced hybrid-closed loop was comparably smaller. This pattern was also reflected in the subgroup analysis.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Real-world glycaemic and person-reported outcomes one year after Tandem Control IQ™ initiation in children and adults with type 1 diabetes
    De Meulemeester, J.
    Valgaerts, L.
    De Block, C.
    Van Huffel, L.
    Ballaux, D.
    Spincemaille, K.
    Taes, Y.
    Lapauw, B.
    Massa, G.
    den Brinker, M.
    Messaaoui, A.
    Gies, I.
    Keymeulen, B.
    Mathieu, C.
    Gillard, P.
    DIABETOLOGIA, 2024, 67 : S65 - S65
  • [32] Real-World Glycemic Outcomes of &gt;400 Adults with Type 2 Diabetes Using the Omnipod 5 Automated Insulin Delivery (AID) System with Cloud-Based Data Management
    Peters, Anne L.
    Pasquel, Francisco J.
    Huyett, Lauren M.
    Snow, Kenneth
    Mendez, Jose J.
    Hadjiyianni, Irene
    Ly, Trang T.
    DIABETES, 2023, 72
  • [33] Insulin Pump Therapy in Type 1 Diabetes-a Real-World Study of Mortality and Clinical Outcomes
    Haughton, Sophie
    Riley, David
    Arshad, Muhammad Fahad
    Azmi, Shazli
    Malik, Rayaz A.
    Alam, Uazman
    Iqbal, Ahmed
    DIABETES, 2024, 73
  • [34] GLYCEMIC OUTCOMES WITH OPEN-SOURCE AUTOMATED INSULIN DELIVERY SYSTEMS AFTER 12 MONTHS OF USE IN ADULTS WITH TYPE 1 DIABETES
    Amuedo-Dominguez, S.
    Ramirez-Belmar, M.
    Antequera-Gonzalez, M.
    Rodriguez-Acebron, N.
    Tafur-Garcia, L.
    Gomez-Gimenez, F.
    Soto-Moreno, A.
    Azriel-Mira, S.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A110 - A111
  • [35] Prevent hypoglycaemia when using automated insulin delivery systems in type 1 diabetes requires near normal glycaemic variability
    Monnier, Louis
    Colette, Claude
    Renard, Eric
    Benhamou, Pierre-Yves
    Aouinti, Safa
    Molinari, Nicolas
    Owens, David
    DIABETES & METABOLISM, 2025, 51 (01)
  • [36] REAL-WORLD EVIDENCE OF AUTOMATED INSULIN DELIVERY (AID) USE BY INDIVIDUALS WITH TYPE 2 DIABETES (T2D)
    Fabris, C.
    Brown, S.
    Stumpf, M.
    Kovatchev, B.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A48 - A48
  • [37] COMPARISON OF GLYCAEMIC CONTROL WHEN TRANSITIONING TO AN HYBRID CLOSED-LOOP INSULIN DELIVERY SYSTEM IN PEOPLE WITH TYPE 1 DIABETES: A SINGLE CENTRE OBSERVATIONAL STUDY
    Corcillo, A.
    Le Dizes, O.
    Wojtusciszyn, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A3 - A3
  • [38] Automated insulin delivery use in adults with type 1 diabetes not meeting glycaemic targets despite treatment with insulin pump and CGM: a randomised controlled trial
    Christensen, M. B.
    Ranjan, A. G.
    Rytter, K.
    McCarthy, O. M.
    Schmidt, S.
    Norgaard, K.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S386 - S386
  • [39] Outcomes after 1 year in adults using Omnipod 5: Real-world data from a UK diabetes centre
    Stimson, Roland H.
    Strachan, Mark W. J.
    Dover, Anna R.
    Wright, Rohana J.
    Forbes, Shareen
    McRobert, Gayle
    Gibb, Fraser W.
    DIABETIC MEDICINE, 2024, 41 (12)
  • [40] Use of Closed-Loop Insulin Therapy in Older Adults with Type 1 Diabetes: Real-World Experience
    Toschi, Elena
    Slyne, Christine
    Atakov-Castillo, Astrid
    Munshi, Medha
    DIABETES, 2021, 70